Malignant Pleural Effusion Market Summary
The Malignant Pleural Effusion market is witnessing significant momentum as healthcare systems across the globe grapple with rising cancer burdens and the associated complications of pleural disease. According to DelveInsight analysis, the Malignant Pleural Effusion Market Size was found to be more than USD 2 billion in the leading markets – the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan – in 2025.
Among the 7MM, the largest Malignant Pleural Effusion market share of more than USD 1 billion was captured by the United States in 2025, and it is projected to continue with a positive growth trajectory throughout the forecast period.
In 2025, the US recorded the highest Malignant Pleural Effusion Incident Cases among the 7MM, totalling approximately 180,000 cases. The rise in Malignant Pleural Effusion Cases in the US is attributed to increased cancer incidence and survival rates and improved healthcare access, resulting in heightened awareness of the condition.
The current Malignant Pleural Effusion market research underscores that the market predominantly depends on drainage procedures due to the absence of approved therapies and the severe nature of the disease, which necessitates often painful interventions. A range of palliative treatment options is currently available, including:
- Systemic cancer therapy
- Thoracentesis
- Tube thoracostomy
- Pleurodesis with sclerosants
- Pleural catheter placement
- Pleuroperitoneal shunts
- Pleurectomy
All existing approaches are aimed at managing symptoms and improving patient comfort rather than achieving curative outcomes.
It is recommended that talc pleurodesis – particularly via thoracoscopic poudrage with large-bore drains – be used as the preferred treatment for MPE due to its high success rates and effectiveness in symptom relief. Indwelling pleural catheters (IPC) can be considered as an alternative, as they provide similar symptom relief and shorter hospital stays, though they are associated with higher adverse event rates. Nonsteroidal analgesics are recommended for pain management, as they do not impact pleurodesis success.
Malignant Pleural Effusion Emerging Therapies are investigating diverse mechanisms to address multiple facets of the disease. Among them, PTS500 – a small-molecule candidate from Gongwing Biopharma – is currently being evaluated in Phase II clinical trials, signaling growing pharmaceutical investment in this space.
The lack of epidemiological studies on Malignant Pleural Effusion limits understanding of its incidence and risk factors, hindering early diagnosis and evidence-based treatment strategies. This gap results in inconsistent management, reduced clinical trial development, inadequate resource allocation, and poor healthcare planning, ultimately affecting patient outcomes and limiting advancements in Malignant Pleural Effusion therapy.
Explore the full DelveInsight report on Malignant Pleural Effusion market size, share, and emerging treatment outlook
Malignant Pleural Effusion Therapies
The current pipeline of emerging therapies targeting MPE reflects growing industry interest. Key investigational candidates include:
- PTS500 – Gongwing Biopharma (Phase II)
- M701 – Wuhan YZY Biopharma
- RSO-021 – RS Oncology
Malignant Pleural Effusion Overview and Diagnosis
MPE is an effusion characterized by the presence of malignant cells, where fluid and cancer cells accumulate between the chest wall and the lung. It is a common but serious condition associated with poor quality of life, significant morbidity, and high mortality. MPE is a frequent manifestation in patients with metastatic disease and is most commonly observed in lung cancer, followed by Breast Cancer, lymphoma, gynecological cancers, and malignant mesothelioma.
Diagnosis of MPE relies on a combination of imaging and pathological tools. Chest ultrasonography is effective in assessing pleural effusion characteristics and guiding procedures. Computed Tomography (CT) can identify pleural abnormalities, though it demonstrates lower sensitivity than other methods. Positron emission tomography-computed tomography (PET-CT) offers high specificity for staging pleural disease. Cytology, while widely used, has limited sensitivity. Pleural biopsy – particularly when guided by imaging – remains the gold standard due to its high sensitivity and specificity, and medical thoracoscopy provides both diagnostic and therapeutic benefits for eligible patients.
Current Malignant Pleural Effusion Treatment Landscape
The Malignant Pleural Effusion market insight reveals a treatment environment primarily driven by drainage-based procedures. Currently, Malignant Pleural Effusion Treatment is largely dependent on thoracentesis, pleurodesis, and indwelling pleural catheters, which are employed for symptom management rather than disease modification.
The Malignant Pleural Effusion Market faces substantial challenges due to the lack of curative treatments and the ongoing dependence on symptomatic procedures. While these methods offer short-term relief, high recurrence rates and procedural complications underscore the urgent need for pharmaceutical innovations that can alter the disease course.
Malignant Pleural Effusion market growth is anticipated to rely heavily on epidemiological studies that identify patient populations most likely to benefit from new therapies. Understanding incidence and survival rates will be pivotal for guiding drug development strategies. While emerging treatments may address existing gaps, their commercial success will depend on robust clinical results and timely regulatory approvals.
To address the unmet needs in the US market, major pharmaceutical players are proactively advancing their pipelines, including:
- PTS500 by Gongwing Biopharma
- RSO-021 by RS Oncology
- M701 by Wuhan YZY Biopharma
These candidates are expected to revolutionize Malignant Pleural Effusion Treatment during the forecast period.
Malignant Pleural Effusion Unmet Needs
The unmet needs in MPE management represent some of the most critical gaps between current practice and optimal patient care. Key areas requiring immediate attention include:
- Improved early detection and diagnosis – Current diagnostic tools lack the sensitivity needed for early-stage identification, delaying timely interventions
- Lack of epidemiological studies – Insufficient population-level data limits understanding of true incidence, risk stratification, and regional disease burden
- Prognostic and therapeutic markers – There is a pressing need for validated biomarkers that can guide treatment selection and predict therapeutic response
- Lack of targeted therapies – No approved disease-modifying or curative pharmacological treatments currently exist, leaving patients entirely dependent on palliative procedures
Bridging these gaps will be fundamental to driving meaningful progress in the Malignant Pleural Effusion market trends and improving long-term patient outcomes.
Malignant Pleural Effusion Epidemiology
Key Findings from MPE Epidemiological Analysis and Forecast
- The total number of Malignant Pleural Effusion Incident Cases across the 7MM reached approximately 480,000 in 2025
- In the US, females accounted for approximately 100,000 incident cases and males for nearly 70,000 incident cases in 2025; incident cases are expected to rise due to genetic predispositions and environmental factors increasing susceptibility to MPE among lung cancer patients
- Across EU4 and the UK, there were approximately 50,000 incident cases related to breast cancer and more than 25,000 cases due to lymphoma in 2025, with both figures projected to increase during the forecast period
- Japan recorded nearly 50,000 symptomatic cases and approximately 12,000 asymptomatic cases of Malignant Pleural Effusion in 2025, with symptom-specific incidence projected to rise
Malignant Pleural Effusion Companies
The competitive landscape of the Malignant Pleural Effusion market trends is being shaped by a focused group of companies advancing novel therapeutic candidates:
- Gongwing Biopharm
- Wuhan YZY Biopharma
- RS Oncology
- Genelux Corporation
Malignant Pleural Effusion Drug Updates – Recent Developments
- In March 2024, RS Oncology reported two abstracts with comprehensive preclinical and translational data supporting RSO-021, accepted for poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR)
- In June 2024, RS Oncology reported positive data from the Phase I clinical trial of RSO-021, reinforcing its therapeutic potential in MPE management
Malignant Pleural Effusion Market Outlook
The Malignant Pleural Effusion Therapeutics Market currently lacks FDA-approved curative treatments, relying instead on palliative interventions such as thoracentesis, pleurodesis, and indwelling pleural catheters. While these approaches help manage symptoms by reducing fluid buildup and alleviating dyspnea, their effectiveness is temporary, with high recurrence rates. Additionally, several procedures carry the risk of complications such as infection and pain, further challenging long-term disease management and emphasizing the need for advanced therapeutic development.
Key regional outlook highlights include:
- Among the 7MM, EU4 and the UK collectively accounted for the second-largest Malignant Pleural Effusion Market Size at approximately USD 750 million in 2025, a figure expected to rise with the anticipated launch of emerging therapies. The region also currently lacks EMA-approved treatments and faces challenges of high recurrence rates and limited long-term effectiveness with existing palliative interventions.
- Japan’s Malignant Pleural Effusion Market Size reached nearly USD 200 million in 2025. The Japanese market is uniquely influenced not only by pharmacological treatments but also by drainage procedures, which continue to play a significant role in disease management and reimbursement structures.
As the pipeline matures and regulatory pathways become clearer, the overall Malignant Pleural Effusion market is poised for meaningful transformation, offering opportunities for early movers to establish leadership in an underserved therapeutic category.
Download the comprehensive Malignant Pleural Effusion market research report and forecast today
Conclusion
The Malignant Pleural Effusion market stands at a critical inflection point, driven by an unmet clinical need for curative or disease-modifying therapies. With a global market exceeding USD 2 billion in 2025, rising cancer incidence rates, and a growing pipeline of investigational candidates, the landscape is evolving rapidly. Bridging epidemiological gaps, advancing biomarker research, and accelerating regulatory pathways will be essential to unlocking the market’s full potential and improving outcomes for the nearly half a million patients diagnosed annually across the 7MM.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail:abhishek@delveinsight.com
